Rare Disease Trial, By Invitation NCT06786754 Sponsor: IRCCS Policlinico S. Donato Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, By Invitation

NCT06786754
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 years or older who are willing to sign a consent form to take part.
  • People diagnosed with Marfan syndrome and a thoracic aortic aneurysm (an enlarged blood vessel in the chest), whether they are being monitored or are scheduled for heart surgery.
  • People with a thoracic aortic aneurysm not linked to a genetic syndrome, whether they are being monitored or are scheduled for heart surgery.
  • Healthy volunteers who have no known disease affecting the aorta or chest area.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have any of the following cardiovascular risk factors: high blood pressure, high cholesterol or fats in the blood, diabetes, a smoking habit, or a history of heart or blood vessel disease.
  • People who have taken corticosteroids, steroids, or fluoroquinolone antibiotics within the six months before joining the trial, or who are on long-term immunosuppressive therapy including oral or topical steroids applied to the area being studied.
  • People who have a history of keloid scarring (a type of raised, overgrown scar tissue that forms after skin injury).
  • People who have a known allergy to anaesthetic drugs.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
IRCCS Policlinico S. Donato
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Fibroblasts phenotype: cell morphology and migration; Fibroblasts phenotype: cell morphology and migration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov